



Atty. Dkt. No. 081356-0207

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Eiji MORI et al.
Title: ANTI-TRAIL-R ANTIBODIES
Appl. No.: 10/721,763
Filing Date: 11/26/2003
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date June 7, 2004

Michael M.A. M.
By Reg No. 34,717

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

for

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>Date Submitted: June 7, 2004</p> <p>(use as many sheets as necessary)</p>				<p>Complete if Known</p>	
Sheet	1	of	1	Application Number	10/721,763
				Filing Date	11/26/2003
				First Named Inventor	Eiji MORI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	081356-0207

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1		Japan 10-327878		Smithkline Beecham Corp.	12/15/1998		
	A2		WO 98/46643		Millennium Biotherapeutics Inc.	10/22/1998		
	A3		WO 98/51793		Genentech, Inc.	11/19/1998		
	A4		WO 98/35986		Immunex Corporation	8/20/1998		
	A5		WO 99/64461		Genentech Inc.	12/16/1999		
	A6		WO 02/079377		Human Genome Sciences, Inc.	10/10/2002		
	A7		WO 02/085946		Immunex Corporation	10/31/2002		
	A8		WO 01/19861 A2		Genentech Inc.	3/22/2001		
	A9		WO 03/042367 A2		Human Genome Sciences, Inc.	5/22/2003		
	A10		WO 98/41629		Human Genome Sciences, Inc.	9/24/1998		
	A11		WO 00/66156		Human Genome Sciences, Inc.	11/9/2000		
	A12		WO 03/038043 A2		UAB Research Foundation	5/8/2003		
	A13		WO 01/83560		UAB Research Foundation	11/8/2001		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A14	Anan CHUNTHARAPAI et al., "Isotype-Dependent Inhibition of Tumor Growth in Vivo by Monoclonal Antibodies to Death Receptor 4", The Journal of Immunology, Vol. 166, pp. 4891-4898.		
	A15	Kimihisa ICHIKAWA et al., "Tumoricidal Activity of a Novel anti-human DR5 Monoclonal Antibody without Helptocyte Cytotoxicity" , Nature Medicine, Volume 7, Number 8, August 2001, pp. 954-960.		
	A16	Thomas S. GRIFFITH et al., "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies", The Journal of Immunology, 1999, Volume 162: 2597-2605.		

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.